April 2025 was a groundbreaking month for women's health, unveiling crucial developments that will revolutionize care from adolescence to menopause. From FDA nods to groundbreaking research, here’s what you might have missed.

1. Breakthrough Guidance on Breast Cancer Prevention Using Genetics

A pioneering international consensus published in *Cancers* introduces the first evidence-based recommendations on utilizing polygenic risk scores (PRSs) for breast cancer prevention and screening. This innovative tool evaluates risk factors beyond the known BRCA mutations, providing a more personalized approach to women's health. Experts believe this sets the stage for integrating genomics into everyday healthcare practices.

2. Shocking Rise in Firearm Suicide Rates Among Women

A revealing study from Ohio State University has uncovered a startling statistic: nearly 40% of women who die by firearm suicide had no previously recorded mental or physical health issues. As female gun ownership soared to 50% in 2020, the absence of targeted prevention strategies becomes alarmingly clear. With over 8,000 cases examined, this vital research calls for immediate action in public education and intervention to combat this growing crisis.

3. Urinary Incontinence: An Unexpected Cardiovascular Risk

A groundbreaking study in *Preventive Medicine* has discovered that women suffering from urinary incontinence are at a significantly heightened risk for cardiovascular disease, despite not being less active than their counterparts. Analyzing data from over 20,000 women, the study links incontinence to a higher likelihood of serious conditions like type 2 diabetes and stroke, emphasizing the need for routine screenings and further investigation into this alarming connection.

4. New Guidelines Transform Approach to Menopausal Health

The AUA, SUFU, and AUGS have released a revolutionary joint guideline recommending a shift in diagnosing and managing genitourinary syndrome of menopause (GSM). Instead of focusing on hormone levels, healthcare providers should prioritize patient-reported symptoms like vaginal dryness. The guidelines advocate for collaborative decision-making in treatment options and stress that ongoing symptom management is essential, marking a new chapter in menopausal care.

5. Gepotidacin: A New Hope in Gonorrhea Treatment

A phase 3 clinical trial has shown that gepotidacin (Blujepa; GSK), a revolutionary oral antibiotic, is almost as effective as ceftriaxone combined with azithromycin for treating uncomplicated gonorrhea. With a 92.6% success rate in eradicating the infection, gepotidacin presents a more convenient treatment option. While gastrointestinal side effects were noted, they were mild and no serious adverse effects occurred. GSK is set to pursue FDA approval later this year.